---
title: "晨星：阿里健康的銷售額可能已企穩"
description: "晨星分析師 Kai Wang 表示，阿里健康的銷售額可能已企穩，儘管由於疫情影響，上一財年的銷售額基數較高，導致銷售放緩。與阿里健康競爭的京東健康在最近六個月業績向好。Wang 認為阿里健康具備競爭優勢，並預計其 10 月份的財季業績將更為樂觀。晨星將阿里健康的合理價值估計從 4.20 港元上調至 5.40 港元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/258980730.md"
published_at: "2025-09-26T03:23:50.000Z"
---

# 晨星：阿里健康的銷售額可能已企穩

> 晨星分析師 Kai Wang 表示，阿里健康的銷售額可能已企穩，儘管由於疫情影響，上一財年的銷售額基數較高，導致銷售放緩。與阿里健康競爭的京東健康在最近六個月業績向好。Wang 認為阿里健康具備競爭優勢，並預計其 10 月份的財季業績將更為樂觀。晨星將阿里健康的合理價值估計從 4.20 港元上調至 5.40 港元。

晨星分析師 Kai Wang 報告稱，阿里健康本財政年度的銷售額可能已經企穩。由於上一財年受疫情推動的比較基數較高，該公司在截至 3 月份財年的銷售額有所放緩。晨星稱，阿里健康的同行京東健康在截至 6 月底六個月的業績向好。京東健康是阿里健康的主要競爭對手，兩家公司市場份額相近，Wang 認為阿里健康具有競爭優勢。該機構認為，當阿里健康在 10 月份公佈下一財季業績時，其銷售增長預測也將更為樂觀。晨星將對阿里健康合理價值的估計從 4.20 港元上調至 5.40 港元。

### Related Stocks

- [00241.HK - 阿里健康](https://longbridge.com/zh-HK/quote/00241.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alibaba Health's Profit Jumps 65% in Fiscal H1 | Alibaba Health's Profit Jumps 65% in Fiscal H1 | [Link](https://longbridge.com/zh-HK/news/267513586.md) |
| Alibaba Health Information Technology Chairman Resigns | Alibaba Health Information Technology Chairman Resigns | [Link](https://longbridge.com/zh-HK/news/269814202.md) |
| Alibaba Health Announces New Board of Directors | Alibaba Health Information Technology has announced a new board of directors, effective December 15, 2025. The update de | [Link](https://longbridge.com/zh-HK/news/269731909.md) |
| Alibaba Health Information Technology Ltd. held special general meeting | Alibaba Health Information Technology Ltd. held a special general meeting on December 30, 2025, where shareholders appro | [Link](https://longbridge.com/zh-HK/news/271105388.md) |
| How Investors May Respond To Alibaba Health Information Technology (SEHK:241) CEO Shen Difan Also Becoming Chairman | Alibaba Health Information Technology Limited announced that CEO Shen Difan will also become Chairman and head of the No | [Link](https://longbridge.com/zh-HK/news/270579681.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。